Top Markets
Coin of the day
Biocure Technology Inc. Biocure Technology Inc.

Biocure Technology Inc.

CURE
Clasificación en acciones #39915
Biocure Technology Inc., operating with its subsidiary, focuses on the creation... Biocure Technology Inc., operating with its subsidiary, focuses on the creation and market introduction of biopharmaceutical innovations, particularly those involving recombinant technologies and ranibizumab. The company's current development pipeline includes: Interferons-ß, aimed at treating multiple sclerosis. Ranibizumab, a monoclonal antibody fragment designed to address macular degeneration and a related eye condition known as macular edema. Filgrastim, which targets neutropenia – a deficiency of white blood cells that can arise from cancer, bone marrow transplants, chemotherapy, or other medical issues. Additionally, Biocure is conducting research and development into several promising areas: CAR T-cell therapy, which works by identifying and eradicating cancer cells. A vaccine against foot and mouth disease. Various products for promoting hair growth. The firm was established in 2005 and its corporate headquarters are located in Vancouver, Canada.
Precio por acción
$0.00366968
Última sincronización: 2024-07-12
Capitalización bursátil
$299.46K
Cambio (1 día)
-66.77%
Cambio (1 año)
0.00%
País
CA
Comercio Biocure Technology Inc. (CURE)

Categoría

Ganancias de Biocure Technology Inc. (CURE)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Biocure Technology Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Biocure Technology Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE